(Rac)-Nedisertib is primarily investigated for its potential in cancer treatment, particularly as an inhibitor of DNA-dependent protein kinase (DNA-PK). This enzyme plays a critical role in the repair of DNA double-strand breaks, a common issue in cancer cells. By inhibiting DNA-PK, (Rac)-Nedisertib can prevent cancer cells from repairing their DNA, leading to cell death and potentially enhancing the effectiveness of other cancer therapies like radiation and chemotherapy. Research is ongoing to explore its efficacy in various cancer types, including solid tumors and hematologic malignancies. Its application could offer a new therapeutic strategy for patients with resistant or recurrent cancers.